[ad_1]
The NGO analyzed contracts between pharmaceutical companies and vaccine manufacturers for five major potential vaccines, based on data collected by analytics firm Airfinity.
“Access to life-saving vaccines shouldn’t depend on where you live or how much money you have,” said Robert Silverman of the organization’s US division.
“The development and validation of a safe and effective vaccine is essential, but it is equally important to ensure that vaccines are available to everyone,” he said.
The organization analyzed the vaccines being developed by AstraZeneca, the Gamalea Research Institute, Moderna, Pfizer and Sinovac, and estimated that a total of 5.9 billion would be produced. dose. That would be enough for 3 billion. people, given the very high probability that two doses will be needed for one person.
Supply contracts for 5,300 million have already been signed. doses of 2.7 billion. (51%) were bought by developed countries, territories and regions, including the US, UK, European Union, Australia, Hong Kong, Macau, Japan, Switzerland, and Israel.
The remaining 2,600 million. doses promised to developing countries, including India, Bangladesh, China, Brazil, Indonesia and Mexico.
Oxfam estimates that $ 2.5 billion has been allocated to the vaccine being developed by Moderna. dollars (2.1 billion euros) of taxpayer money, but the company intends to make a profit and sell all future doses to rich countries.
Oxfam and other organizations are calling for the vaccine to be free and distributed fairly as needed.
Oxfam added that the estimated cost of vaccinating the entire population of Earth is less than a percentage of the estimated cost of COVID-19 to the global economy.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
